The antitumor promise of furo[2,3- d ]pyrimidine: a 2016–2025 review
RSC Advances · 2026 · 16 (27) · 24808-24821
DOI: 10.1039/d6ra01695b ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift RSC Advances, 2026. Verfasst von Mai A Mansour und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Badr University in Cairo Cairo 11829 Egypt Mai.aly@buc.edu.eg. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
The furopyrimidine scaffold is an emerging core incorporated into numerous anticancer agents.
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Badr University in Cairo Cairo 11829 Egypt Mai.aly@buc.edu.eg.
- Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University Mansoura 35516 Egypt.
ORCID-Profile: Mai A Mansour, Marwan M Abdel Karim, Rania M Gomaa
Zitieren
APA
Mansour, M. A., Elshafei, H. A., Sayed, A. S., Ashour, A. A., Hussein, N. E., Abdel Karim, M. M., Kamel, F. M., Elsayed, N. T., Ahmed, M. R., Seleem, M. T., & Gomaa, R. M. (2026). The antitumor promise of furo[2,3- d ]pyrimidine: a 2016–2025 review. RSC Advances, 16(27), 24808-24821. https://doi.org/10.1039/d6ra01695b
Vancouver
Mansour MA, Elshafei HA, Sayed AS, Ashour AA, Hussein NE, Abdel Karim MM, et al. The antitumor promise of furo[2,3- d ]pyrimidine: a 2016–2025 review. RSC Advances. 2026;16(27):24808-24821. doi:10.1039/d6ra01695b
BibTeX
@article{Mansour2026,
author = {Mansour, Mai A and Elshafei, Haya A and Sayed, Alaa S and Ashour, Aya A and Hussein, Nadia E and Abdel Karim, Marwan M and Kamel, Fares M and Elsayed, Nada T and Ahmed, Mahmoud R and Seleem, Mohamed T and Gomaa, Rania M},
title = {The antitumor promise of furo[2,3- d ]pyrimidine: a 2016–2025 review},
journal = {RSC Advances},
year = {2026},
volume = {16},
number = {27},
pages = {24808--24821},
doi = {10.1039/d6ra01695b}
}
EUVIMED